US approval for Affymax/Takeda's anaemia drug
This article was originally published in Scrip
The US FDA has approved Omontys (peginesatide) for the treatment of anaemia due to chronic kidney disease (CKD) in adults on dialysis, and it will be launched during the second quarter. An aggressive pricing policy is expected, but "for those who may try to determine relative comparative pricing to other ESAs (erythropoiesis-stimulating agents), such an exercise will be challenging because of the different administration schedule", Affymax told Scrip.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.